Statins is an effective drug with proven benefits in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However,several clinical researches indicate that the long-term use of statins may increase the risk of new-onset diabetes mellitus (NODM). Pitavastatin, as a newest form of statins, is called “super statin” because of its better safety and tolerability. The correlation between pitavastatin and NODM risk is inconsistent. Some research indicated that pitavastatin had no negative effect on glucose metabolism, and might even improve insulin resistance. While, some other researchers consider that increased NODM risk is a kind of effect for all statins, including pitavastatin. This review summarizes the research progress on the effect of pitavastatin and glucose metabolism.